A detailed history of Sherbrooke Park Advisers LLC transactions in Catalent, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 24,919 shares of CTLT stock, worth $1.58 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
24,919
Previous 7,556 229.79%
Holding current value
$1.58 Million
Previous $425 Million 255.25%
% of portfolio
0.35%
Previous 0.07%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$56.16 - $60.96 $975,106 - $1.06 Million
17,363 Added 229.79%
24,919 $1.51 Billion
Q2 2024

Aug 14, 2024

BUY
$53.58 - $57.02 $404,850 - $430,843
7,556 New
7,556 $425 Million

Others Institutions Holding CTLT

About Catalent, Inc.


  • Ticker CTLT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 179,896,000
  • Market Cap $11.4B
  • Description
  • Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...
More about CTLT
Track This Portfolio

Track Sherbrooke Park Advisers LLC Portfolio

Follow Sherbrooke Park Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.